Tempero Bio has hit the brakes on a phase 2-stage alcohol use disorder (AUD) candidate while the biotech considers its options, according to the program’s partner. The mGluR5 negative allosteric ...
Baseline Therapeutics, Inc. (“Baseline”), a clinical-stage biotechnology company developing addiction therapeutics, today announced the launch of the company to advance a new generation of ...
Feb 12 (Reuters) - Novo Nordisk’s (NOVOb.CO), opens new tab blockbuster GLP-1 diabetes drug Ozempic led to improvements in some measures of alcohol use disorder in a small trial, researchers reported ...
Several research studies, either in progress or in planning stages, are testing whether GLP-1 agonists can help people who have symptoms of an alcohol use disorder reduce drinking. The goal of the ...
WAUSAU, Wis. (WSAW) - While we do not know the reason behind each drunk driver’s choice to drive under the influence, we can look into some of the factors that play a role, like Alcohol Use Disorder ...
Evidence continues to mount suggesting that GLP-1 drugs may help people cut back on cigarettes, drinking and opioid use. Subscribe to read this story ad-free Get unlimited access to ad-free articles ...
RECLAIM, a Phase 2 trial of pemvidutide in AUD, is currently enrolling GAITHERSBURG, Md., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT) (Nasdaq: ALT), a late clinical-stage biopharmaceutical ...
Since GLP-1s hit the mainstream roughly two years ago, people taking the weight-loss drugs noticed their cravings for food disappear. For some, that extended to alcohol, too. Now, the growing buzz ...
For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don’t just curb their desire to eat; for some, they also lead them to drink ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results